A low CD4 cell count despite viral suppression with HIV treatment is associated with a big increase in mortality risk

Michael Carter
Published: 14 February 2014

A low CD4 cell count is associated with increased mortality risk, even if people are taking virologically effective HIV therapy, an international team of investigators report in the online edition of Clinical Infectious Diseases. People with incomplete CD4 count recovery – a count below 200 cells/mm3 – despite three years of treatment with virologic suppression had a more than two-fold increase in their mortality risk compared to people with more robust immune reconstitution.

“We identified older age, transmission via male heterosexual sex or IDU [injecting drug use], lower CD4 count at start of the suppressed period and longer time from initiation of cART [combination antiretroviral therapy] to start of the virally suppressed period as risk factors for incomplete CD4 cell recovery,” write the authors.

They believe their findings underline the importance of earlier HIV diagnosis and the prompt initiation of therapy. The investigators also urge that patients with incomplete CD4 count recovery should be closely monitored for certain diseases, including hepatitis and non-HIV-related cancers.

Modern antiretroviral therapy is very effective at suppressing viral load. This control of HIV replication allows the immune system to strengthen and CD4 count to increase.  People with virologic and immunologic responses to HIV therapy now have a normal life expectancy.

However, it is well known that a significant proportion of people taking anti-HIV drugs do not have a robust increase in their CD4 count, even though treatment is controlling viral load. The clinical consequences of this discordant response to treatment are unclear.

Investigators from Europe and North America therefore designed a study to elucidate the factors associated with an incomplete CD4 response to HIV therapy in people with long-term virologic suppression. They also compared mortality rates according to CD4 count and analysed the relationship between incomplete immune recovery and specific causes of death.

The study population comprised 5550 patients enrolled in 53 cohorts across Europe and North America. All the participants had a CD4 count below 200 cells/mm3 when they started HIV therapy. They were followed for a median of 3.4 years.

The majority (85%) achieved an increase in their CD4 cell count to above 200 cells/mm3 after three years of viral suppression.

Risk factors for incomplete CD4 count recovery were older age, HIV transmission risk group (heterosexual males and injecting drug users), a viral load below 100,000 copies/ml at the start of therapy, lower CD4 count at baseline, and longer interval between initiation of treatment and suppression of viral load.

A total of 175 (3%) participants died. The mortality rate was 8% among people with incomplete CD4 count recovery compared to 2% among individuals whose CD4 count increased to 200 cells/mm3. Therefore individuals who did not attain a CD4 count of 200 cells/mm3 despite long-term virologic suppression, had a significantly increased mortality risk compared to people with an immunologic response to treatment (aHR = 2.6; 95% CI, 1.86-3.81).

The cumulative five-year mortality rate was 12% among participants with a CD4 cell count below 200 cells/mm3 after three years of suppression. This compared to a 2% rate among participants with CD4 counts above 500 cells/mm3.  

As regards causes of death, the investigators found that incomplete immune recovery was associated not only with an increased risk of all-cause mortality (aHR = 2.75; 95% CI, 1.71-3.70), but also of non-AIDS-related mortality (aHR = 2.61; 95% CI, 1.61-4.23), hepatitis-related death (aHR = 6.76; 95% CI, 1.93-23.74) and mortality related to non-AIDS-defining cancers (aHR= 2.89; 95% CI, 1.44-5.28). 

“Since 15% of treated HIV-positive patients have a CD4 count < 200 cells/mm3 after long-term viral suppression, prognosis of such patients is a major concern,” write the authors.

“Our data underline the importance of the early diagnosis of HIV and treatment with cART before patients have a low CD4 count,” the investigators conclude. “Virally suppressed patients with low CD4 counts should be monitored closely for diseases not conventionally considered HIV-related, especially non-AIDS cancers and liver disease.”


Engsig FN et al. Long-term mortality in HIV positive individuals virally suppressed for more than three years with incomplete CD4 recovery. Clin Infect Dis, online publication ahead of print, 2014.

This news report is also available in Russian.

Tell us why you visited aidsmap today

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?


Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.